NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

KALV

KalVista Pharmaceuticals Inc

Jul 01 • 11:58AM ET

11.65

Dollar change +0.34
Percentage change 3.05	%

Healthcare • Biotechnology • USA • NASD

Peers: FATE RARE CORT QURE VKTX VSTM PVLA LPTX XERS XBIO

| Held by: VTI IWM VXF XBI IWO IBB VTWO LFSC VHT FESM

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.73	Insider Own	22.58%	Shs Outstand	49.49M	Perf Week	-0.43%
Market Cap	579.19M	Forward P/E	-	EPS next Y	-2.98	Insider Trans	2.78%	Shs Float	38.49M	Perf Month	-1.27%
Enterprise Value	432.69M	PEG	-	EPS next Q	-0.84	Inst Own	88.37%	Short Float	16.25%	Perf Quarter	0.95%
Income	-175.87M	P/S	-	EPS this Y	-3.28%	Inst Trans	-6.35%	Short Ratio	8.25	Perf Half Y	31.94%
Sales	0.00M	P/B	3.97	EPS next Y	16.13%	ROA	-90.20%	Short Interest	6.25M	Perf YTD	37.54%
Book/sh	2.93	P/C	2.29	EPS next 5Y	22.36%	ROE	-150.50%	52W High	15.50 -24.84%	Perf Year	-3.32%
Cash/sh	5.09	P/FCF	-	EPS past 3/5Y	-12.44% -20.06%	ROIC	-70.24%	52W Low	7.30 59.59%	Perf 3Y	12.78%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	10.61% 6.95%	Perf 5Y	3.37%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-18.75%	Oper. Margin	-	ATR (14)	0.79	Perf 10Y	-89.21%
Dividend Ex-Date	-	Quick Ratio	10.44	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	41.85	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	10.44	EPS Q/Q	-10.23%	SMA20	-8.40%	Beta	-0.04	Target Price	26.44
Payout	-	Debt/Eq	0.74	Sales Q/Q	-	SMA50	-6.50%	Rel Volume	0.92	Prev Close	11.31
Employees	150	LT Debt/Eq	0.73	Earnings	Mar 12 BMO	SMA200	6.75%	Avg Volume	758.45K	Price	11.65
IPO	Apr 09, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	-6.24% -	Trades		Volume	287,618	Change	3.05%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-31-25	Initiated	JMP Securities	Mkt Outperform	$19
Jan-07-25	Initiated	TD Cowen	Buy	$30
Dec-18-24	Initiated	BofA Securities	Buy	$22
Jun-15-20	Initiated	H.C. Wainwright	Buy	$30
Jul-29-19	Initiated	SVB Leerink	Outperform	$31
Mar-20-19	Initiated	Needham	Buy	$35
Oct-30-18	Initiated	Jefferies	Buy	$30
Sep-21-18	Initiated	Cantor Fitzgerald	Overweight
Aug-31-17	Initiated	BTIG Research	Buy	$18

Jun-26-25 06:03PM	Pendopharm® and KalVista® Partner to Bring First Oral On-Demand HAE Treatment to Canada (PR Newswire)
07:00AM	KalVista Pharmaceuticals Enters into Licensing Agreement with Pendopharm to Commercialize Sebetralstat for HAE in Canada (Business Wire)
Jun-20-25 08:03AM	How KalVista Pharma Is Taking On A Rare But Deadly Disease (Investor's Business Daily)
Jun-18-25 09:31AM	FDA Commissioner envisions fewer delays, more clinical trial flexibility and AI use (Clinical Trials Arena)
Jun-16-25 07:00AM	KalVista Pharmaceuticals Presents New Data at the European Academy of Allergy and Clinical Immunology Congress 2025 on the Efficacy of Sebetralstat for the On-demand Treatment of HAE Attacks Among Patients Receiving Long-Term Prophylaxis (Business Wire)
05:00AM	Loading…
05:00AM	FDA to miss approval deadline for Kalvista drug due to resource constraints (BioPharma Dive)
Jun-13-25 04:05PM	KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints (Business Wire)
Jun-05-25 07:00AM	KalVista Pharmaceuticals to Present New Sebetralstat Data at the European Academy of Allergy and Clinical Immunology Congress 2025 (Business Wire)
Jun-03-25 04:01PM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-02-25 07:00AM	KalVista Pharmaceuticals Medical Congress Presentations Highlight Potential of Sebetralstat to Redefine Hereditary Angioedema Management (Business Wire) +9.49%
May-29-25 07:00AM	KalVista Pharmaceuticals to Present at the Jefferies Global Healthcare Conference (Business Wire)
May-22-25 07:00AM	KalVista Pharmaceuticals to Present New Sebetralstat Data With 10 Abstracts Accepted at Upcoming Medical Meetings (Business Wire)
May-02-25 07:00AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-30-25 07:00AM	KalVista Pharmaceuticals to Present at the Citizens Life Sciences Conference (Business Wire) +5.28%
Apr-12-25 12:42AM	KalVista: Poised For Rare Disease Transformation (Seeking Alpha)
10:27AM	Loading…
Apr-08-25 10:27AM	KalVista licenses commercialisation rights for HAE to Kaken in Japan (Pharmaceutical Technology) -10.26%
06:30AM	KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan (Business Wire)
Apr-02-25 07:00AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-31-25 07:00AM	KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-26-25 11:14AM	KalVista Pharmaceuticals enrols all subjects in hereditary angioedema drug trial (Clinical Trials Arena)
Mar-25-25 07:00AM	KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial (Business Wire)
Mar-12-25 07:00AM	KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update (Business Wire)
Mar-10-25 07:00AM	KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema (Business Wire)
Mar-04-25 07:00AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-03-25 07:00AM	KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting (Business Wire)
Feb-24-25 07:00AM	KalVista Pharmaceuticals to Present at Upcoming Investor Conferences (Business Wire)
Feb-21-25 07:00AM	KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting (Business Wire) -5.73%
Feb-10-25 07:00AM	KalVista Pharmaceuticals Presents New Sebetralstat Data at the Western Society of Allergy, Asthma & Immunology 2025 Annual Meeting (Business Wire)
Feb-04-25 07:00AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.75%
Jan-21-25 07:00AM	KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema (Business Wire) +5.42%
06:30AM	Loading…
Jan-08-25 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.94%
Dec-16-24 07:00AM	KalVista Appoints Jeb Ledell as Chief Operating Officer (Business Wire)
Dec-05-24 06:30AM	KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update (Business Wire)
Dec-04-24 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-26-24 07:00AM	KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of Directors (Business Wire)
Nov-12-24 06:30AM	KalVista Pharmaceuticals to Present at Upcoming Investor Conferences (Business Wire)
Nov-05-24 07:29AM	KalVista Secures $184M Financing for Sebetralstat Launch (TipRanks)
06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-04-24 07:05AM	KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million (Business Wire) +9.61%
07:00AM	KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust (Business Wire)
Oct-28-24 06:30AM	KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology (Business Wire)
Oct-18-24 06:30AM	KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) (Business Wire)
Oct-04-24 12:29PM	KalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema Forum (Business Wire)
Oct-02-24 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-30-24 06:30AM	KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema (Business Wire) -6.16%
Sep-26-24 06:30AM	KalVista Pharmaceuticals Announces Nine Abstracts Accepted for Presentation at the HAEi Global Angioedema Forum (GAF) (Business Wire) +5.71%
Sep-10-24 07:00AM	KalVista Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference (Business Wire) -5.56%
06:30AM	KalVista Appoints Brian Piekos as Chief Financial Officer (Business Wire)
Sep-06-24 06:30AM	KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024 (Business Wire)
Sep-05-24 06:30AM	KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update (Business Wire)
Sep-04-24 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-03-24 06:30AM	KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema (Business Wire) -7.62%
Aug-29-24 06:30AM	KalVista Pharmaceuticals Announces Six Abstracts Accepted for Presentation at the 2024 Bradykinin Symposium (Business Wire)
Aug-15-24 06:30AM	KalVista Announces Validation of Marketing Authorization Application by the European Medicines Agency for Sebetralstat for Hereditary Angioedema (Business Wire)
Aug-02-24 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-11-24 02:52PM	KALV Stock Earnings: KalVista Pharma Misses EPS for Q4 2024 (InvestorPlace)
06:30AM	KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results (Business Wire)
Jul-02-24 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-27-24 06:30AM	KalVista Initiates KONFIDENT-KID Trial for On-demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Children Aged 2 to 11 (Business Wire) +6.54%
Jun-18-24 06:30AM	KalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-demand Treatment for Hereditary Angioedema (Business Wire)
Jun-06-24 06:30AM	KalVista Pharmaceuticals Presents Data at Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024 (Business Wire)
Jun-04-24 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-03-24 06:30AM	KalVista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024 (Business Wire)
May-31-24 04:09PM	KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema (Business Wire)
May-24-24 06:30AM	KalVista Pharmaceuticals Announces Ten Abstracts Accepted for Presentation at the European Academy of Allergy and Clinical Immunology Congress 2024 (Business Wire)
May-21-24 06:30AM	KalVista Pharmaceuticals to Present at Upcoming Investor Conferences (Business Wire)
May-02-24 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-01-24 06:30AM	KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year (Business Wire) +7.31%
Apr-22-24 06:30AM	KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors (Business Wire)
Apr-05-24 06:30PM	ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors (Barrons.com)
Apr-03-24 06:30AM	KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference (Business Wire)
Apr-02-24 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-18-24 06:30AM	KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas (Business Wire)
Mar-12-24 06:30AM	KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat (Business Wire)
Mar-11-24 06:30AM	KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update (Business Wire) -8.77%
Mar-08-24 06:30AM	KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas (Business Wire)
Mar-07-24 06:30AM	KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer (Business Wire)
Mar-06-24 06:30AM	KalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma Conference (Business Wire)
Mar-04-24 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-27-24 06:30AM	KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting (Business Wire) +6.79%
Feb-26-24 06:30AM	KalVista Pharmaceuticals Presents Additional Phase 3 KONFIDENT Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting (Business Wire) +8.82%
Feb-20-24 06:30AM	KalVista Pharmaceuticals Awarded UK Innovation Passport for Sebetralstat (Business Wire) -7.13%
Feb-16-24 06:30AM	KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting (Business Wire)
Feb-15-24 06:30AM	KalVista Pharmaceuticals Announces Pricing of a $160.1 Million Public Offering of Common Stock and Pre-Funded Warrants (Business Wire)
Feb-14-24 04:18PM	KalVista Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (Business Wire)
Feb-13-24 07:10AM	UPDATE 1-KalVista meets main goals in late-stage trial for genetic disease (Reuters) -7.42%
06:40AM	KalVista meets main goals in late-stage trial for skin condition treatment (Reuters)
06:30AM	KalVista Pharmaceuticals Reports Phase 3 KONFIDENT Trial Meets All Endpoints for Sebetralstat as First Oral On-demand Therapy for Hereditary Angioedema (Business Wire)
01:30AM	Kalvista pill succeeds in late-stage study for rare swelling disorder (BioPharma Dive)
Feb-02-24 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-01-24 12:02PM	Hedge Fund and Insider Trading News: David Einhorn, Crispin Odey, Bill Ackman, Stanley Druckenmiller, Ken Griffin, Burke Herbert Financial Services (BHRB), KalVista Pharmaceuticals, Inc. (KALV), and More (Insider Monkey)
Jan-13-24 03:12AM	Insider Sell: Chief Scientific Officer Edward Feener Sells 22,679 Shares of KalVista ... (GuruFocus.com)
Jan-12-24 03:03AM	Insider Sell: Chief Scientific Officer Edward Feener Sells 17,321 Shares of KalVista ... (GuruFocus.com)
Dec-30-23 09:02AM	Insider Sell: CEO Thomas Crockett Sells 30,000 Shares of KalVista Pharmaceuticals Inc (KALV) (GuruFocus.com)
Dec-29-23 06:45AM	16 Most Promising Long-Term Stocks According to Analysts (Insider Monkey)
Dec-20-23 06:30AM	KalVista Pharmaceuticals Announces Publication of First Oral Factor XIIa Data in Frontiers in Pharmacology (Business Wire)
Dec-07-23 04:49PM	KalVista Pharmaceuticals Inc (KALV) Reports Second Fiscal Quarter Results (GuruFocus.com) -9.03%
06:30AM	KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update (Business Wire)
Dec-05-23 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-23-23 05:14AM	Insider Sell Alert: CEO Thomas Crockett Offloads Shares of KalVista Pharmaceuticals Inc (GuruFocus.com)

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	Jun 09 '25	Sale	14.50	7,169	103,950	315,074	Jun 10 05:00 PM
Audhya Paul K.	CHIEF MEDICAL OFFICER	May 23 '25	Sale	11.31	2,146	24,272	113,026	May 27 04:06 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	May 23 '25	Sale	11.31	1,926	21,782	98,189	May 27 04:05 PM
Audhya Paul K.	CHIEF MEDICAL OFFICER	May 22 '25	Sale	11.88	2,689	31,933	110,172	May 23 04:26 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	May 22 '25	Sale	11.88	2,317	27,516	96,990	May 23 04:25 PM
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	May 22 '25	Sale	11.88	9,999	118,743	306,618	May 23 04:24 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	May 19 '25	Sale	11.84	2,600	30,791	95,557	May 20 07:28 PM
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	May 19 '25	Sale	11.84	3,808	45,097	293,367	May 20 07:28 PM
Audhya Paul K.	CHIEF MEDICAL OFFICER	May 19 '25	Sale	11.84	2,776	32,876	106,611	May 20 07:27 PM
Venrock Healthcare Capital Par	10% Owner	Apr 09 '25	Buy	9.42	25,000	235,500	5,303,985	Apr 11 05:22 PM
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	Mar 07 '25	Sale	11.97	6,669	79,828	287,811	Mar 10 06:43 PM
Audhya Paul K.	CHIEF MEDICAL OFFICER	Feb 24 '25	Sale	10.02	2,394	23,988	102,940	Feb 25 08:37 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	Feb 24 '25	Sale	10.02	1,918	19,218	93,952	Feb 25 08:36 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	Feb 18 '25	Sale	9.82	2,601	25,553	92,745	Feb 19 08:47 PM
Audhya Paul K.	CHIEF MEDICAL OFFICER	Feb 18 '25	Sale	9.82	3,125	30,701	100,334	Feb 19 08:46 PM
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	Feb 18 '25	Sale	9.82	5,104	50,143	278,855	Feb 19 08:46 PM
Venrock Healthcare Capital Par	10% Owner	Feb 12 '25	Buy	9.23	100,000	923,000	5,217,285	Feb 14 07:45 PM
Venrock Healthcare Capital Par	10% Owner	Feb 13 '25	Buy	9.33	61,700	575,661	5,278,985	Feb 14 07:45 PM
Venrock Healthcare Capital Par	10% Owner	Feb 07 '25	Buy	9.29	73,649	684,199	5,086,445	Feb 11 07:51 PM
Venrock Healthcare Capital Par	10% Owner	Feb 11 '25	Buy	9.18	26,703	245,134	5,117,285	Feb 11 07:51 PM
Venrock Healthcare Capital Par	10% Owner	Feb 10 '25	Buy	9.14	4,137	37,812	5,090,582	Feb 11 07:51 PM
Venrock Healthcare Capital Par	10% Owner	Jan 30 '25	Buy	8.76	43,707	382,873	4,986,480	Feb 03 07:42 PM
Venrock Healthcare Capital Par	10% Owner	Feb 03 '25	Buy	9.22	14,562	134,262	5,012,796	Feb 03 07:42 PM
Venrock Healthcare Capital Par	10% Owner	Jan 31 '25	Buy	8.89	11,754	104,493	4,998,234	Feb 03 07:42 PM
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	Dec 09 '24	Sale	9.75	7,627	74,363	274,596	Dec 09 09:08 PM
Audhya Paul K.	CHIEF MEDICAL OFFICER	Nov 26 '24	Sale	9.87	2,187	21,586	97,012	Nov 27 08:45 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	Nov 26 '24	Sale	9.87	1,963	19,378	91,142	Nov 27 08:43 PM
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	Nov 18 '24	Sale	9.26	14,400	133,294	266,598	Nov 19 07:19 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	Nov 18 '24	Sale	9.26	7,192	66,573	89,980	Nov 19 07:18 PM
Audhya Paul K.	CHIEF MEDICAL OFFICER	Nov 18 '24	Sale	9.26	8,077	74,766	94,199	Nov 19 07:18 PM
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	Sep 09 '24	Sale	12.19	7,352	89,622	250,800	Sep 10 08:31 PM
Audhya Paul K.	CHIEF MEDICAL OFFICER	Aug 23 '24	Sale	12.40	2,135	26,474	83,745	Aug 26 08:00 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	Aug 23 '24	Sale	12.40	1,916	23,758	85,676	Aug 26 07:58 PM
Audhya Paul K.	CHIEF MEDICAL OFFICER	Aug 19 '24	Sale	12.01	7,973	95,782	80,880	Aug 21 09:26 PM
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	Aug 19 '24	Sale	12.01	14,215	170,769	242,527	Aug 21 09:25 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	Aug 19 '24	Sale	12.01	7,102	85,318	84,467	Aug 21 09:25 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KALV

KalVista Pharmaceuticals Inc

Upgrade your FINVIZ experience